Jim Allison launches new institute aimed at speeding drug development and raising 'survival curve for all cancers'
Jim Allison’s name is linked to a 2018 Nobel Prize, the immune system-activating cancer med Yervoy and a host of accolades across his multi-decade career in immunotherapy and T cell research.
Now, as part of MD Anderson Cancer Center’s push for new breakthroughs this decade, he’s launched an eponymous institute alongside scientific director Padmanee Sharma and operations leader Raghu Kalluri.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.